ChromaDex Corp. announced that the results of a preclinical study conducted by Nestlé were published last month in the journal Nature Communications, a peer-reviewed open access scientific journal published by the Nature Publishing Group.
LOS ANGELES, Oct. 17, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that the results of a preclinical study conducted by Nestlé were published last month in the journal Nature Communications, a peer-reviewed open access scientific journal published by the Nature Publishing Group. The study investigated the impact on the liver when its cells lose the ability to use the nutrient nicotinamide riboside (NR). The preclinical study concluded that the tissue’s natural ability to utilize NR is important for maintaining resilience during periods of metabolic stress such as a high-fat diet. It is also the first study to show the physiological consequences that arise when cells lose the ability to use NR.
In December 2018, ChromaDex entered into a license and supply agreement for NIAGEN® (nicotinamide riboside) with Nestlé Health Science, a global leader pioneering quality science-based nutritional health solutions.
The body uses NR to boost nicotinamide adenine dinucleotide, or NAD, a molecule found in cells that powers metabolism and helps cells be more resilient in the face of metabolic stress. Recent studies have shown preclinically that NR has unique NAD-boosting properties in the liver and physiological benefits for aged blood stem cells. This new study provides additional evidence that NR is physiologically distinct from other NAD precursors and may play a unique role in maintaining cellular health and resiliency in the face of metabolic stress.
“This is an important study by Dr. Canto and our partners at Nestlé,” said Dr. Matthew Roberts, Chief Scientific Officer at ChromaDex. “The findings highlight an emerging area of research in the physiological uniqueness of NR as an NAD precursor and furthers our understanding of the role NR plays in liver health.”
Dr. Carles Cantó, scientist at Nestlé, who is the corresponding author of the study said, “This is the first paper suggesting a functional uniqueness of NR that cannot be mimicked by other precursors and indicates that there might exist true situations of NR deficit and not simply NAD+ deficit.”
For additional information on the science supporting NR and Niagen, please visit www.chromadex.com.
About ChromaDex:
ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.
Forward-Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects”, “anticipates”, “intends”, “estimates”, “plans”, “potential”, “possible”, “probable”, “believes”, “seeks”, “may”, “will”, “should”, “could” or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018, ChromaDex’s Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
ChromaDex Media Contact:
Alex Worsham, Senior Director of Global Corporate Communications
310-388-6706 ext. 689
alexw@chromadex.com
ChromaDex Investor Relations Contact:
Brianna Gerber, Vice President of FP&A and Investor Relations
949-419-0288 ext. 127
briannag@chromadex.com
